The retail math
Branded GLP-1 medications (semaglutide, tirzepatide) retail at $900-1,400 per month. On a group health plan that covers them, that translates to roughly $11,000-17,000 per user per year. At even 5% workforce utilization, the per-employee cost on a 500-person workforce climbs into seven figures annually.
Why coverage decisions are hard
Most employers covering GLP-1s see significant cost impact in year one and are forced to either reduce coverage (eligibility tightening, prior authorization, dollar caps) or pay through it. Both choices have employee-satisfaction consequences. Reducing coverage on a medication employees know about is harder than never offering it in the first place.
Where a SIMERP-side GLP-1 benefit fits
When the GLP-1 benefit lives on the SIMERP side (via the program's clinical evaluation and compound pharmacy network), it does not run through your group plan and therefore does not affect your group plan's specialty-drug line. The cost to your business is the SIMERP admin fee, not the retail GLP-1 price.
Comorbidity displacement
The harder-to-measure benefit: GLP-1 use is associated with measurable reductions in cardiovascular events, type 2 diabetes progression, and several other chronic-condition trajectories that drive employer healthcare cost long-term. The 5-year claim-displacement effect is real but not visible in year-one renewal math.
What to ask a vendor
- What is the clinical eligibility process for GLP-1 access in your program?
- What is the medication-supply continuity plan when branded supply is constrained?
- What ongoing clinical supervision is included with the prescription?
- How is the program structured to avoid liability for off-label prescribing?
Vendors that are loose with these answers are signaling something about their clinical rigor. The vendors worth taking seriously give you clean answers and a clinician on the call.